Welcome to the Qsymia®(phentermine and topiramate
extended-release) capsules Program Registration Page
Register to participate in an upcoming
peer-to-peer educational forum in your area.
Qsymia is the only FDA-approved, once-daily prescription treatment indicated for chronic weight management.
This program will evaluate the impact of obesity on related risk factors and discuss the clinical guidelines and evolving treatment landscape in obesity. The presentation will review the unique pharmacologic profile of once-daily Qsymia, its clinical efficacy in attaining significant weight loss, and its safety profile. Lastly, the program will review the approach to patient management and dosage flexibility with Qsymia.
To register, please complete the following information. Your registration confirmation will be sent via e-mail.
Please review the list of programs carefully as multiple programs may be offered in your area.
* Required fields. † Please provide your NPI number or select "I don't have an NPI number."
Please be advised that according to PhRMA guidelines, which VIVUS, Inc. fully upholds, it would not be appropriate for the company to pay for spouses or guests to attend this meeting. Therefore, spouses and guests will not be permitted to attend any activities related to this meeting, including meal functions, as these are considered part of the official program. If your spouse or a guest is traveling with you, any charges or expenses related to his or her presence will be your personal responsibility.
PRIVACY AND REPORTING POLICY
Personal information provided above will not be used for any other purpose beyond this peer-to-peer program and compliance reporting purposes.
Consistent with federal and state reporting obligations including, but not limited to, the Federal Physician Payment Sunshine Act, VIVUS, Inc. will disclose any transfers of value given to health care providers attending our programs.
Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity or idiosyncasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.